Seaport Therapeutics, Inc. Common Stock SPTX | NASDAQ
|2026-08-31
Company Overview:
0.5 Year SPTX Performance Metrics:
Build Custom Charts
SPTX Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for SPTX
Based on past 0.5-year performance, here are SPTX growth metrics:
Share price CAGR of -2.4%
Dividend CAGR of +0%
Using SPTX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| SPTX (DRIP) | SPTX - No DRIP | |
|---|---|---|
| Current Price | $19.60 | $19.60 |
| Start Shares | 510.20 | 510.20 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 510.20 | 510.20 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $18.22 | $19.60 |
| Total Dividends | $0 | $0 |
| Final Value | $9,296 | $10,000 |
NOTE: Above numbers are our estimate based on SPTX's Dividend and Price CAGR over past 0.5 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Seaport Therapeutics, Inc. Common Stock (SPTX) had its IPO on 2026-05-01, and is traded on NASDAQ stock exchange.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
SPTX website: https://www.seaporttx.com
DCF Model — SPTX
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
